Indivior gets a speedy review for opioid addiction drug as FDA vows to fight a crisis
With the FDA vowing to do everything in its power to help fight the country’s opioid addiction crisis, regulators have handed Indivior a pass onto the inside track at the agency, promising a speedy review of its opioid addiction therapy.
The FDA’s priority review process slashes 4 months off the standard 10-month approach. That means Indivior {LON: INDV} will be up for a decision by the end of November for RBP-6000, a once-monthly slow-release version of the opioid dependence drug buprenorphine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.